Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy

Pharmacotherapy

Volumn 32, Issue 6, 2012, Pages 538-545

  Hsu, Alice Jenh ^a   Carson, Kathryn A ^b   Yung, Rex ^c   Pham, Paul A ^c,d  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

HIV; Human immunodeficiency virus; Midazolam; Prolonged sedation; Protease inhibitor

Indexed keywords

ATAZANAVIR; LOPINAVIR; MIDAZOLAM; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ANESTHESIA INDUCTION; ANESTHESIA LEVEL; ARTICLE; BRONCHOSCOPY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ANTAGONISM; FEMALE; HEPATITIS B; HEPATITIS C; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; RISK FACTOR; SEDATION; SIDE EFFECT; VIRUS LOAD;

ADULT; BRONCHOSCOPY; COHORT STUDIES; DATABASES, FACTUAL; DEEP SEDATION; DRUG INTERACTIONS; ELECTRONIC HEALTH RECORDS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDAZOLAM; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864615840     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2011.01045.x     Document Type: Article

References (20)

1. Midazolam. In: DRUGDEX System [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically
2. Agouron Pharmaceuticals, Inc. Viracept (nelfinavir) package insert. La Jolla, CA, 2011
3. Agouron Pharmaceuticals, Inc. Rescriptor (delavirdine mesylate) package insert. La Jolla, CA, 2001
4. Bristol-Myers Squibb Company. Sustiva (efavirenz) package insert. Princeton, NJ, 2010
5. ViiV Healthcare. Lexiva (fosamprenavir calcium) package insert. Research Triangle Park, NC, 2011
6. Bristol-Myers Squibb Company. Reyataz (atazanavir sulfate) package insert. Princeton, NJ, 2011
7. Abbott Laboratories. Kaletra (lopinavir/ritonavir) package insert. North Chicago, IL, 2011
8. Roche Farma SA. Invirase (saquinavir mesylate) package insert. Leganes, Spain, 2010
9. Abbott Laboratories. Norvir (ritonavir) package insert. North Chicago, IL, 2010
10. Merck Sharp & Dohme Corp. Crixivan (indinavir sulfate) package insert. Whitehouse Station, NJ, 2010
11. Boehringer Ingelheim Pharmaceuticals, Inc. Aptivus (tipranavir) package insert. Ridgefield, CT, 2011
12. Tibotec Pharmaceuticals. Prezista (darunavir ethanolate) package insert. Raritan, NJ, 2010
13. Palkama VJ, Ahonen J, Neuvonen PJ, et al. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999;66:33-9
14. Schmitt C, Hofmann C, Riek M, Patel A, Zwanziger E. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy 2009;29(10):1175-81
15. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60
16. Gastaldo JM, Neidig JL, Para MF, et al. The clinical significance of the drug interaction between protease inhibitors and midazolam. Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto, Canada. Abstract 422
17. Pleym H, Spigset O, Kharasch ED, Dale O. Gender differences in drug effects: Implications for anesthesiologists. Acta Anaesthesiol Scand 2003;47(3):241-59
18. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64(2):133-43
19. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008;49(4):358-68
20. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85(1):64-70.